Novacyt « Terug naar discussie overzicht

Novacyt de volgende biotech raket!

trab33
1
quote:

RW1963 schreef op 17 augustus 2021 12:14:


[...]

Daar weet Voda van alles over te vertellen ;-)

telkens als ik van u posts mag lezen zijn het misplaatste ,,,,,,,,,,,,,,,
U zou beter uw commentaar posten op het forum ."speel op de man "op het jaardraadje "den besten "
RW1963
4
quote:

trab33 schreef op 17 augustus 2021 14:43:


[...]
telkens als ik van u posts mag lezen zijn het misplaatste ,,,,,,,,,,,,,,,
U zou beter uw commentaar posten op het forum ."speel op de man "op het jaardraadje "den besten "


Nog steeds hier? Hoe vaak ben jij al geschorst geweest? Dat zegt toch ook genoeg!!!
Sun120
0
Nieuwe website voor novacyt testandyou.org kunnen we dan nu terug spreken dat ze stilaan terug alles op orde aan het zetten zijn??
€URO-Trader
0
De meesten zijn murw geslagen en hebben hun geluk elders gezocht. Op dit niveau zeer interessant. Blijft een aandeel van volatiliteit, minstens 50.
platteey
2
Novacyt S.A.
18 August 2021

Novacyt S.A.



("Novacyt", the "Company" or the "Group")



Half Year Update



Investor meeting at 13:00 BST / 14:00 CEST



Paris, France and Camberley, UK - 18 August 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a half year update in advance of its investor meeting today.



Six months revenue ended 30 June 2021



£'000

H1 2021

H1 2020

YoY Growth

YoY Growth

Actual

%

Total Group Revenue

94,710

63,252

31,458

50%

DHSC Revenue

40,759

18,406

22,353

121%

Non-DHSC Revenue

53,951

44,846

9,105

20%



Unaudited revenue for the first half of 2021 increased over 50% to £94.7 million, compared to £63.3 million for the first half of 2020. Of this total revenue, £54 million came from a mixture of overseas sales and a growing UK private testing market, leading to non-DHSC revenue growing 20% year-on-year.



As announced on 21 May 2021, the DHSC sales of £40.8 million are in dispute.



Business update

Contract award with DHSC under PHE framework

Primerdesign, a wholly owned subsidiary of Novacyt, has been awarded a new contract under the PHE National Microbiology Framework, effective immediately, for the supply of PROmate® COVID-19 tests to the NHS. The PROmate® COVID-19 tests have been developed to run on the Company's q16 and q32 PCR instrument platforms. The q16 and q32 near patient PCR instrument platforms using the PROmate® COVID-19 test have been validated and can be used at select NHS hospitals. The contract is valued at up to £4.7m and will last until 31 March 2022. There are no minimum purchase levels as part of this contract.



Separately, there is no further update to the announcement on 22 June 2021 in relation to the Company's second supply contract with the DHSC which is in dispute.



Non-governmental organisation long-term agreements

Novacyt has entered into a two-year Long-Term Agreement (LTA) with the World Health Organization (WHO) for the supply of its genesig® COVID-19 tests. In addition, the Company has received confirmation from UNICEF that its existing LTA with the organisation has been extended by 12 months to July 2022. To date, Novacyt has shipped orders to a total of eight countries under the UNICEF LTA since September 2020.



Private sector testing

Overall, UK private market sales, which currently includes COVID-19 testing in film, media, travel and corporate industries, increased significantly in Q2 2021 compared to Q1 2021. The Company believes it is well placed to continue to support this growth during the second half of the year.



As part of its expansion in private testing, the Company has also signed a supply contract initially for genesig® COVID-19 products with Excalibur Healthcare Services, who have invested in new laboratory services in Cambridge, UK, to support COVID-19 testing of private clients.



A key product expected to support second half growth in private testing will be the Company's PROmate® COVID-19 2G (2 gene) test. As announced on 23 April 2021, the Company's CE-IVD PROmate® COVID-19 (1 gene) test identifies the SARS-CoV-2 ORF1ab gene. Due to an emerging need in some countries, the Company launched a second CE-IVD PROmate® COVID-19 test to identify both the SARS-CoV-2 ORF1ab gene and nsp16 gene.



Outlook

The Company expects continued strong growth in private testing as markets and travel re-open and, as the Northern Hemisphere heads into winter, the potential for higher infection rates will increase the need for COVID-19 testing. Since the start of 2020, the Company has launched 16 new CE-IVD products, and expects to launch a further 10 by the end of 2022.



The Company therefore reiterates revenue guidance of £100 million for the full year, excluding DHSC revenues, as announced on 22 June 2021.



Investor meeting

As announced on 5 August 2021, certain members of the Executive Management Team will present the Company's strategy alongside an operational update, followed by a live Q&A at 13:00 BST / 14:00 CEST today. This is being hosted through the digital online platform, Investor Meet Company, with dial-in details also available for attendees once registered.



Investors already registered to the platform and added to meet the Company will automatically be invited. If new to the platform, investors and analysts can sign up to Investor Meet Company for free and add to meet Novacyt via the following link: www.investormeetcompany.com/novacyt-s...



Graham Mullis, Group CEO of Novacyt, commented:

"Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private and public health settings to expand existing, and support new, partnerships. Throughout the pandemic, NHS testing demand has remained a key priority for the Company and the contract award under the PHE National Microbiology Framework is a testament to our continued commitment.



"We believe our long-term strategy also supports the growth of Novacyt post-COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the COVID-19 testing opportunity but also ensure we are well placed, with both technologies and partners, for sustainable growth beyond COVID-19. We therefore believe Novacyt is well positioned to continue to build on its business transformation."



This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Opstapelen
0
Prima RNS, promate 2g de kartrekker
100m is wel en magere outlook vind ik(Buiten DHSC)

en natuurlijk geen piep over de dispute
platteey
0
quote:

Opstapelen schreef op 18 augustus 2021 08:19:


Prima RNS, promate 2g de kartrekker
100m is wel en magere outlook vind ik(Buiten DHSC)

en natuurlijk geen piep over de dispute
in Engeland positief onthaald, beter geen te hoge verwachtingen creëren en dan overschooten
Erg chebbi
0
Overseas sales...daarmee is het buiten engeland gezegd. Om eerlijk te zijn is het imo een obligaat bericht.
Ze zijn alive and kicking. Er is geen reden om de koers opwaarts te doen laten gaan. Dat betekent doorgaans...hengels uitgooien en bodemvissen.

Edit: Ik wacht op een sprong omhoog om mijn twee handelsporties kwijt te raken.
voda
5
Keurige cijfers. En ja, die outlook is voorzichtig natuurlijk. Jammer dat die dispute nog steeds als een zwarte schaduw boven die cijfers en outlook hangt. Krijg het gevoel dat die rechtzaken nog lang niet klaar zijn. Dit is/wordt een bikkelharde strijd.

Op basis van de cijfers is het aandeel duidelijk ondergewaardeerd.

Eens kijken hoe de markt er vandaag (en verder) er over denkt.

Succes toegewenst aan de vasthouders, en eventuele nieuwe instappers vandaag.
voda
1
Eindelijk een mooie koersreactie op de goede cijfers. Dit is weer ouderwets vuurwerk.

€ 4,04 +0,51 (+14,44%)
Erg chebbi
0
66.392 Posts, Pagina: « 1 2 3 4 5 6 ... 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 ... 3316 3317 3318 3319 3320 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 7 dec 2021 17:38
Koers 3,586
Verschil -0,353 (-8,96%)
Hoog 3,920
Laag 3,510
Volume 2.332.963
Volume gemiddeld 1.207.664
Volume gisteren 1.059.162

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront